Abstract
The Trade-Related Aspects of Intellectual Property Rights（TRIPS) requires all member countries of the World Trade Organization (WTO) to introduce a TRIPS-compatible patent law into their countries. Due to the enforcement of TRIPS in 1995, India in 2005 revised its patent law and enacted the Patents (Amendment) Act, 2005. The 2005 ACT included product patent in pharmaceutical field. Due to the new patent law with product patent protection, large foreign capital pharmaceutical companies one after another re-entered the Indian market and started engaging in both R&D and production targeting the Indian market. However recent data shows the number of patent applications has been declining over the past several years and the number of patented drugs launched in India did not increase so rapidly. This study analyzes transitions of business models of foreign pharmaceutical companies in India based on the patent application data, and the trend of patented drugs in the market. A data analysis and a series of interviews with stakeholders were conducted. As a result of both a quantitative and a qualitative analysis, it was found that foreign pharmaceutical companies changed their strategies in the Indian pharmaceutical market. Since India was required to introduce product patents in the pharmaceutical area, there have been many arguments that once India introduces a product patent, the Indian pharmaceutical industry may decline due to the rapid introduction of foreign pharmaceutical products in the country; many academic papers were published in this context during that time. However, since 2005, when product patents were actually introduced in India, few academic papers were published. This study is unique as it discusses the effects of the introduction of product patents on the Indian pharmaceutical market.
Highlights
As a result of the implementation of the World Trade Organization (WTO)’s Trade-Related Aspects of Intellectual Property Rights (TRIPS), which took effect in 1995, all members of the WTO, including advanced countries and developing countries, are required to introduce TRIPS-compatible patent law, including product patents, in their countries
The number of patent applications in the field of pharmaceuticals has been declining over the past several years and the number of patented drugs in Indian market has not significantly increased in India since 2005
Once India was required to introduce product patents, many stake holders including Indian people, Indian pharmaceutical industry and international NGO/NPOs that send Indian drugs to the Third World, argued once a product patent is introduced in India, Indian pharmaceutical industry might decline because foreign capital pharmaceutical products would rapidly enter the Indian market and might occupy it
Summary
As a result of the implementation of the World Trade Organization (WTO)’s Trade-Related Aspects of Intellectual Property Rights (TRIPS), which took effect in 1995, all members of the WTO, including advanced countries and developing countries, are required to introduce TRIPS-compatible patent law, including product patents, in their countries. A member of WTO, introduced product patent in 2005 in pharmaceutical field. Once India was required to re-introduce product patent, very large pharmaceutical companies so-called Mega pharma companies one after another re-entered the Indian market targeting the country with the world second largest population. These Mega pharma companies applied patents to IPO and started engaging in R&D and manufacturing their patented products. This study analyzed Mega pharma companies’ strategies toward India – one of the phar-merging countries and No 3 pharmaceutical country in the world on volume – based on IPR data and marketing data.
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
